Ken Ono
Research Subjects
Research Interests
Ken Ono has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Michiyo Shirai
Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan
2 shared publications - Shinji Kageyama
Kageyama Urology Clinic, Shizuoka 420-0838, Japan
2 shared publications - Shizuo Yamada
University of Shizuoka, Japan
2 shared publications - Jun Mochizuki
TechnoSuruga Laboratory Co., Ltd., Shizuoka 424-0065, Japan
1 shared publication - Koji Nagashima
TechnoSuruga Laboratory Co., Ltd., Shizuoka 424-0065, Japan
1 shared publication
Latest Publications
- Open Access
Beneficial Effects of Enoki Mushroom Extract on Male Menopausal Symptoms in Japanese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
With the increase in average life expectancy, age-related male menopause has become a cause of decreased quality of life in men. The present study investigated the efficacy and safety of powdered enoki mushroom extract containing adenosine (test food) for menopausal symptoms in middle-aged and elderly men based on an evaluation of Heinemann’s Aging Males’ Symptoms (AMS) scores. The test food and placebo were administered to healthy men with AMS scores of 27–49 for 12 weeks. AMS score (primary endpoint) and testosterone level (secondary endpoint) were evaluated before and 12 weeks after the intake of the test food and placebo. The intake of the test food for 12 weeks significantly improved the sexual subscale of the AMS. In the cumulative χ2 test, the number of subjects showing high improvement was significantly higher in the test food group than in the placebo food group. In a stratified analysis of subjects divided into two groups based on a change in total testosterone levels of <0.5 ng/mL and ≥0.5 ng/mL after the intake of the test food, the number of subjects with increased total testosterone levels of ≥0.5 ng/mL was significantly higher in the test food group than in the placebo group. These results suggest the beneficial effects of enoki mushroom extract on symptoms of male menopause.
Open AccessBeneficial Effects of Enoki Mushroom Extract on Male Menopausal Symptoms in Japanese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
With the increase in average life expectancy, age-related male menopause has become a cause of decreased quality of life in men. The present study investigated the efficacy and safety of powdered enoki mushroom extract containing adenosine (test food) for menopausal symptoms in middle-aged and elderly men based on an evaluation of Heinemann’s Aging Males’ Symptoms (AMS) scores. The test food and placebo were administered to healthy men with AMS scores of 27–49 for 12 weeks. AMS score (primary endpoint) and testosterone level (secondary endpoint) were evaluated before and 12 weeks after the intake of the test food and placebo. The intake of the test food for 12 weeks significantly improved the sexual subscale of the AMS. In the cumulative χ2 test, the number of subjects showing high improvement was significantly higher in the test food group than in the placebo food group. In a stratified analysis of subjects divided into two groups based on a change in total testosterone levels of <0.5 ng/mL and ≥0.5 ng/mL after the intake of the test food, the number of subjects with increased total testosterone levels of ≥0.5 ng/mL was significantly higher in the test food group than in the placebo group. These results suggest the beneficial effects of enoki mushroom extract on symptoms of male menopause.
- Open Access
Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Saw palmetto berry extract (SPE) is the most commonly consumed supplement by men with benign prostatic hyperplasia (BPH). The oral administration of SPE was previously shown to significantly attenuate urodynamic symptoms in the hyperactive bladders of female rats by increasing bladder capacity and prolonging the micturition interval. The amelioration of urodynamic symptoms by SPE may be partly attributed to its binding to muscarinic receptors in the urinary bladder and its inhibition of vanilloid receptors on afferent nerves. Therefore, SPE may be pharmacologically effective at mitigating lower urinary tract symptoms (LUTS) in women. The efficacy and safety of a 12-week treatment with SPE in adult women with urinary symptoms were examined herein. The daytime frequency score in the core lower urinary symptom score (CLSS) questionnaire was significantly lower in women with LUTS treated with SPE for 12 weeks than in the placebo group. A subgroup analysis revealed that SPE alleviated the symptoms of daytime frequency (CLSS Q1) and nocturia (CLSS Q2) in a subset of subjects with a CLSS Q5 score of 1 or higher. The daytime frequency of urination in overactive bladder symptom score (OABSS) Q1 was also significantly improved by the SPE treatment. In conclusion, the present study is the first to demonstrate the potential of SPE to mitigate LUTS in adult women.
Open AccessBeneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Saw palmetto berry extract (SPE) is the most commonly consumed supplement by men with benign prostatic hyperplasia (BPH). The oral administration of SPE was previously shown to significantly attenuate urodynamic symptoms in the hyperactive bladders of female rats by increasing bladder capacity and prolonging the micturition interval. The amelioration of urodynamic symptoms by SPE may be partly attributed to its binding to muscarinic receptors in the urinary bladder and its inhibition of vanilloid receptors on afferent nerves. Therefore, SPE may be pharmacologically effective at mitigating lower urinary tract symptoms (LUTS) in women. The efficacy and safety of a 12-week treatment with SPE in adult women with urinary symptoms were examined herein. The daytime frequency score in the core lower urinary symptom score (CLSS) questionnaire was significantly lower in women with LUTS treated with SPE for 12 weeks than in the placebo group. A subgroup analysis revealed that SPE alleviated the symptoms of daytime frequency (CLSS Q1) and nocturia (CLSS Q2) in a subset of subjects with a CLSS Q5 score of 1 or higher. The daytime frequency of urination in overactive bladder symptom score (OABSS) Q1 was also significantly improved by the SPE treatment. In conclusion, the present study is the first to demonstrate the potential of SPE to mitigate LUTS in adult women.